Harmony Biosciences Holdings (HRMY) — Cash Flow-to-Debt Ratio
Harmony Biosciences Holdings (HRMY) has a Cash Flow-to-Debt Ratio of 0.29x as of September 2025, meaning its operating cash flow of $108.73 Million could theoretically repay 0% of its total liabilities ($373.10 Million) in one year. See HRMY free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Harmony Biosciences Holdings Cash Flow-to-Debt Ratio (2018–2024)
Historical debt coverage capacity for Harmony Biosciences Holdings across 7 annual periods. Also explore Harmony Biosciences Holdings (HRMY) equity growth momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Harmony Biosciences Holdings (2018–2024)
Year-by-year debt coverage analysis for Harmony Biosciences Holdings. For market capitalisation and broader financial context, see Harmony Biosciences Holdings (HRMY) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.65x | $219.82 Million | $340.05 Million | ▲ +1.5% |
| 2023 | 0.64x | $219.39 Million | $344.46 Million | ▲ +19.5% |
| 2022 | 0.53x | $144.47 Million | $271.03 Million | ▲ +33.5% |
| 2021 | 0.40x | $98.56 Million | $246.94 Million | ▲ +4511.0% |
| 2020 | -0.01x | $-2.98 Million | $329.89 Million | ▲ +98.6% |
| 2019 | -0.64x | $-75.44 Million | $118.29 Million | ▲ +87.3% |
| 2018 | -5.00x | $-38.80 Million | $7.75 Million | — |